Moderna Surges 94% in 2026 Amid Leadership Restructuring and Upcoming Product Launches

Moderna (MRNA) has surged 94% year-to-date in 2026, outperforming peers like Pfizer (+4%) and Novavax (+41%). The stock rally follows a leadership restructuring aimed at preparing for up to three vaccine launches by 2027-2028. Despite the strong performance, Wall Street maintains a 'Reduce' rating on Moderna with a $37 price target.

By David Moadel Tue, June 16, 2026 at 10:21 PM GMT+3 4 min read · Yahoo Finance · June 16, 2026, 19:21 UTC

Tickers: $MRNA $NVAX $PFE

Topics: leadership change Moderna Novavax Pfizer vaccine stocks

Read the full article at Yahoo Finance

More World news

Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC